ReviewEuropean journal of nuclear medicine and molecular imaging2012
Radiolabelled peptides for oncological diagnosis.
Review in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 77 citations in OpenAlex.
- The novel [RSC advances · 2026Article
- CXCR4-targeted PET imaging of glioblastoma using [EJNMMI radiopharmacy and chemistry · 2026Article
- A Novel Luciferase-Based Reporter Gene Technology for Simultaneous Optical and Radionuclide Imaging of Cells.International journal of molecular sciences · 2024Article
- Development and Validation of an Analytical HPLC Method to Assess Chemical and Radiochemical Purity of [Molecules (Basel, Switzerland) · 2022Article
- [International journal of molecular sciences · 2021Article
- Advances in GLP-1 receptor targeting radiolabeled agent development and prospective of theranostics.Theranostics · 2020Review
- The functions and applications of A7R in anti-angiogenic therapy, imaging and drug delivery systems.Asian journal of pharmaceutical sciences · 2019Review
- Systemic delivery and SPECT/CT in vivo imaging ofScientific reports · 2019Article
- PEGylated peptide to TIP1 is a novel targeting agent that binds specifically to various cancers in vivo.Journal of controlled release : official journal of the Controlled Release Society · 2019Article
- Cholecystokinin-2 Receptor Targeting with Novel C-terminally Stabilized HYNIC-Minigastrin Analogs Radiolabeled with Technetium-99m.Pharmaceuticals (Basel, Switzerland) · 2019Article
- GPCR Modulation in Breast Cancer.International journal of molecular sciences · 2018Review
- Article
- Biodistribution and Internal Radiation Dosimetry ofCancer biotherapy & radiopharmaceuticals · 2018Article
- Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting.Theranostics · 2018Article
- Imaging of Integrin αCancer biotherapy & radiopharmaceuticals · 2017Article
- New Insights in the Design of Bioactive Peptides and Chelating Agents for Imaging and Therapy in Oncology.Molecules (Basel, Switzerland) · 2017Review
- Developing Targeted Hybrid Imaging Probes by Chelator Scaffolding.Bioconjugate chemistry · 2017Article
- Radiolabeled bombesin derivatives for preclinical oncological imaging.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2017Review
- Peptide-based imaging agents for cancer detection.Advanced drug delivery reviews · 2017Review
- Fully automated GMP production of [American journal of nuclear medicine and molecular imaging · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiolabelled receptor-binding peptides targeting receptors (over)expressed on tumour cells are widely under investigation for tumour diagnosis and therapy. The concept of using radiolabelled receptor-binding peptides to target receptor-expressing tissues in vivo has stimulated a large body of research in nuclear medicine. The (111)In-labelled somatostatin analogue octreotide (OctreoScan) is the most successful radiopeptide for tumour imaging, and was the first to be approved for diagnostic use. Based on the success of these studies, other receptor-targeting peptides such as cholecystokinin/gastrin analogues, glucagon-like peptide-1, bombesin (BN), chemokine receptor CXCR4 targeting peptides, and RGD peptides are currently under development or undergoing clinical trials. In this review, we discuss some of these peptides and their analogues, with regard to their potential for radionuclide imaging of tumours.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.